H. Stahlberg, K. Goehler, Michel Guillaume
Oct 1, 1999
Citations
0
Influential Citations
3
Citations
Quality indicators
Journal
Drugs
Abstract
Gatifloxacin is a new fluoroquinolone developed by Kyorin Pharmaceutical Co. Ltd in Japan; it is currently under clinical development in Japan by Kyorin and in Europe by Grünenthal GmbH (Germany), through a licensing agreementwithKyorin. Compared with other quinolones, gatifloxacin has a broader spectrum of antibacterial activity in vitro and in vivo against Gram-positive and Gram-negative bacteria, mycoplasma and intracellular organisms. Because of its excellent antibacterial activity (which includes Streptococcus pneumoniae and other species causing pneumonia), its favourable pharmacokinetic properties and good tissue penetration, gatifloxacin is indicated for the once-daily treatment of respiratory and urinary tract infections. The objectives of this study were twofold: i) to determine the clinical safety and tolerability of increasing single oral doses (200, 400, 600 and 800mg) of gatifloxacin; and ii) to evaluate the linearity of the pharmacokinetics of gatifloxacin enantiomers.